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As preparatory 
work and preliminary 
construction progresses on 
the National Bio and Agro-
defense Facility site north 
of Kansas State University, 
the opportunities for the 
private sector continue to 
grow. 
The arrival of the 
$650 million Department 
of Homeland Security 
facility will foster local and 
regional development, university leaders say, 
and may create new partnerships for K-State, 
the Manhattan community and animal 
health companies both inside and outside the 
Kansas City Animal Health Corridor.
“Only time will tell how many and what 
kind of private sector opportunities will 
arise because of NBAF,” said Ron Trewyn, 
K-State’s vice president for research. “But 
I think it’s pretty clear with all the Animal 
Health Corridor companies that are in the 
area that there is great potential.”
When the Department of Homeland 
Security named Manhattan as the official 
site for NBAF in early 2009, Trewyn was 
amazed at the number of pharmaceutical 
companies that started contacting K-State, 
the Manhattan Chamber of Commerce and 
the Kansas Department of Commerce. While 
some of the larger companies were interested 
in expanding to the Manhattan area, other 
smaller animal health companies talked 
about completely relocating to the area.
Companies of all sizes were interested 
in opportunities both at K-State and 
in the Animal Health Corridor region, 
which stretches from Manhattan, Kan., 
to Columbia, Mo. This region is already a 
hotspot for animal health — containing one-
third of the world’s marketplace for animal 
health companies and including more than 
13,000 employees — but the addition of 
NBAF makes it even more appealing.
“Some of the companies in this region 
are expressing interest in what might be 
available near the NBAF site in Manhattan,” 
Trewyn said. “But we’re also being contacted 
by animal health companies that aren’t 
currently located in the Animal Health 
Corridor.”
With construction of the lab itself slated 
to begin in early 2012, it’s likely that more 
companies will be attracted to the area. 
While there is limited land close to campus 
for companies to build, Trewyn noted that 
space is available throughout the Manhattan 
area. He pointed to the 25-acre K-State 
Research Park on Manhattan Avenue east 
of the NBAF site as a potential place for 
companies to locate. 
While negotiations with companies are 
still in the early stages, the arrival of NBAF 
will also give K-State the ability to compete 
for science or policy-related programs, 
particularly related to zoonotic and animal 
diseases. NBAF’s emphasis on animal 
vaccinations, as well as new antibiotic and 
antiviral treatments, will help attract animal 
health companies that focus on infectious 
diseases or diagnoses.
“When it comes right down to it, 
Manhattan is going to become the epicenter 
for the world’s animal health,” said Daniel 
Thomson, who is the Jones professor of 
production medicine and epidemiology for 
the K-State College of Veterinary Medicine. 
His research group has used K-State facilities 
to develop the E. coli O157: 
H7 vaccine for cattle. 
Thomson sees huge 
potential for animal health 
private industry because 
NBAF and K-State’s 
Biosecurity Research 
Institute will provide new 
biosafety level 3 and level 
4 laboratories, where 
scientists can research 
pathogens such as foot-and-
mouth disease, swine fever 
and anthrax. 
“I think it will attract some of the 
best and brightest minds to work in these 
facilities,” Thomson said. “The collaboration 
that K-State will be able to do with those 
facilities will help K-State recruit the best 
and brightest students as well.”
The development of animal vaccines 
will be particularly important, Thomson 
said. When researchers are able to develop 
vaccines, they’ll need industry partners to 
produce the vaccines. In many cases, it makes 
sense for animal health and pharmaceutical 
companies to be geographically close to the 
researchers.
“When I look at NBAF and K-State as 
a whole, the way I describe Manhattan is 
the front gate to the west,” Thomson said. 
“Our function at Kansas State University is 
to be the gate — that ability to scientifically 
and independently review the things that are 
coming from the industry to improve the 
health and performance of animals.
“We’re at the point in time where 
industry and agriculture shake hands,” 
Thomson said.
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About the Biosecurity Research Institute
B iocontainment facilities are classified by the Centers for Disease and Prevention 
Control and the National Institutes 
of Health into four distinct levels, 
depending on the nature of the research 
and the biological agents that will be 
used in the laboratory. These levels 
are Biosafety Level 1, 2, 3 or 4, and are 
normally designated as BSL-1, BSL-2, BSL-
3 and BSL-4. 
Biosafety level 1 basically covers 
organisms that are not normally 
hazardous to healthy adults. Biosafety 
level 2 covers organisms and biological 
materials that pose moderate hazards 
to adults and personnel. These 
laboratories also have limited access 
and documented procedures for 
handling biological materials. Biosafety 
level 3 designates work with biological 
materials that could cause serious illness 
— including death — to humans if not 
handled properly. Biological materials 
falling into this category include 
pathogens like the West Nile virus. The 
highest level of biosafety is BSL-4, which 
involves work with biological materials 
where vaccines are not currently 
available and which require workers to 
wear full hazmat-like positive pressure 
suits with self-contained air supplies. 
The Biosecurity Research Institute will 
not be working with any BSL-4 biological 
materials. The BRI is a BSL-3 and BSL-
3Ag facility, the latter an enhanced and 
specialized form of BSL-3 for working 
with livestock. BSL-3Ag incorporates 
almost all the same construction features 
of a BSL-4 facility and must meet specific 
construction standards set by USDA for 
the rooms to be primary containment 
barriers. However, the self-contained 
“space suits” are not required.
At K-State all laboratories are 
inspected by the Environmental 
Health and Safety office. Those using 
biological materials must have their 
activities approved by the Institutional 
Biosafety Committee. These approvals 
follow a prescribed process and include 
site inspections by the Institutional 
Biosafety Committee and University 
Research Compliance Office for facility 
compliance, as well as for appropriate 
documentation for laboratory policies 
and procedures.
In order to work with more hazardous 
biological materials, additional 
external inspections must be made by 
organizations such as the CDC or the U.S. 
Department of Agriculture. This is the 
case with the most rigorously regulated 
biological materials, which are termed 
“select agents.” Facility inspections are 
done for each specific project involving 
a select agent to ensure that the facility 
is configured appropriately, that the 
support staff are trained to safely 
handle the specific select agent, that 
the experimental plans and security 
measures for the select agents are 
appropriate and documented, and 
that the select agent can be used in a 
safe and secure manner for the facility 
personnel and surrounding community.
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Dr. Guy Palmer is the Creighton chair and 
director of the Washington State University 
School for Global Animal Health and the Re-
gents professor of pathology and infectious 
diseases. Dr. Palmer’s goal is to improve the 
control of animal diseases with direct impact 
on human health and well‐being. Within this 
focus, he has led collaborative infectious diseases research programs in southern and eastern Africa, the Middle East, and Latin America, where he currently directs a multi‐institu-
tional research effort studying genetic change in microbial pathogens and the risk for shifts in disease pattern and emergence. 
Dr. Jan Sargeant is the director of the Centre for Public Health and Zoonoses at the University of Guelph in Ontario, Canada. Dr. Sargeant has performed research in 
areas of agri‐food 
public health, policy 
research in micro-
bial food safety, 
perception of risk 
of gastrointestinal 
illnesses, food and 
water safety, and the role of veterinary medicine in public health. She is currently developing a research agenda focused on policy and outcome evaluation issues  
in the prevention of zoonotic disease.
Dr. Alfonso Torres is the  
associate dean for public policy 
in the College of Veterinary 
Medicine at Cornell University. 
Prior to his current position,  
Dr. Torres served as the deputy 
administrator for Veterinary Services of USDA APHIS and U.S. chief veterinary officer and delegate to the World Organization for Animal Health. Dr. Torres was the  
director of the USDA’s Plum Island Animal Disease Center on Plum Island, N.Y., from 1996 to 1999, following three years as chief of the Foreign Animal Disease Diagnos-
tic Laboratory there. Prior to his service at USDA, Dr. Torres held academic positions at the National University of Colombia, the University of Nebraska‐Lincoln, and Cornell 
University. Between academic experiences, Dr. Torres also worked in research and development and marketing of veterinary biologics and diagnostics with two large 
multinational corporations.
Biosecurity Research Institute Advisory Board
Guy Palmer, DVM, Ph.D. Jan Sargeant, DVM, M.S., Ph.D Alfonso Torres, DVM, M.S., Ph.D.
[ “The Biosecurity Research Institute provides a unique resource needed to discover and fully develop innovative approaches to control infectious diseases. While clearly providing new opportunities for K-State faculty and affiliated scientists, the BRI is also 
a regional and national resource that can catalyze research to improve both livestock 
productivity and public health.
]
”
[ “The Biosecurity Research Institute at Kansas State University is unique in its ability to support high containment infectious disease research activities from basic discovery research through live animal and plant experiments. The diversity of approaches also leads to scientists from multiple disciplines working together 
and networking. This dynamic research environment and innovative research facility will produce research 
results that will lead to improved human and animal health in the U.S. and internationally. ]”
[ “The Biosecurity Research Institute’s current capability provides a significant jumpstart for Kansas State University to work in this important field ahead of the construction and activation of the National Bio and Agro-defense Facility, placing K-State as the leading U.S. academic institution in the field of 











Torline: Private Sector Opportunities Abound with the Arrival of NBAF
